Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Trial Profile

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms REASSURE
  • Sponsors Bayer
  • Most Recent Events

    • 02 Jun 2017 The next interim analysis in 2019 will report long-term safety and outcomes on all patients as per result presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 First planned interim analysis results (n=1106, enrolled between 2 Sep 2014 to 22 Sep 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 23 Oct 2014 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top